Global Osteoporosis Drugs Market; Drivers and Restraints in the Healthcare Insustry, MRFR Unleashes the Forecast by 2022

Market Research Future adds the “Global Osteoporosis Drugs Market Research Report - Forecast to 2022” report to their unique and vast collection.

Pune, India - June 12, 2019 /MarketersMedia/ —

Osteoporosis is a disorder that causes a lower bone mass that results in weakening and micro-architectural deterioration of bone tissues.  Osteoporosis makes bones so brittle that a minor injury or even mild stresses like bending over or coughing can cause a fracture. Osteoporosis drugs are useful in the treatment of low bone density, slowing down bone resorption. These medications reduce the likelihood of having fragility fractures.

The global osteoporosis drugs market is well-established, and there are various effective medicines available to treat the disorder which is invariably driving the growth of the market. Moreover, a growing number of drug manufacturers are escalating the market on the global platform, bringing novel medications in the market.

Get Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/2479

Recognizing the colossal traction and gauging the potential of the market to grow in forthcoming years; Market Research Future (MRFR), in its newly published study analysis asserts that the global osteoporosis drugs market will reach a valuation of USD 14,300 MN by 2022, growing at7.2% CAGR over the review period (2017 – 2022).

Additional factors helping the market to grow further include the rise in the geriatric population, gene mutations, changing lifestyle, and addictions such as alcoholism and smoking. Also, drug-induced osteoporosis and rising prevalence of diseases and medical procedures that may cause bone loss such as cancer, autoimmune disorders, thalassemia, and hormonal disorders, are some of the key factors propelling the growth of the market.

Conversely, factors such as the patent expiries of blockbuster medicines, side effects of these drugs, and the availability of generics are impeding the growth of the market. Also, in some cases, osteoporosis shows very low or poor symptoms which obstructs the market growth.

Nevertheless, factors such as substantial technological strides that have made the osteoporosis drugs more effective, increasing the demand for the treatment measures for osteoporosis are expected to fuel the growth of the market. 

Besides, substantial investments transpired into R&D activities, and improving economic conditions would provide impetus to the growth of the market, increasing the healthcare expenditures and access to excellent health care.

Global Osteoporosis Drugs Market – Segments

For ease of understanding, the analysis has been segmented into four key dynamics: -

By Drug Class                                  : Bisphosphonates, Calcitonins, Selective Estrogen Receptor Modulators (SERMs), and Parathyroid Hormone (PTH) among others.

By Route Of Administration     : Oral and Injectable among others.

By Gender                                       : Male and Female

By Regions                                      : North America, Asia Pacific, Europe, and the Rest-of-the-World.

Global Osteoporosis Drugs Market – Regional Analysis

The North American region, heading with the increasing prevalence of osteoporosis is estimated to retain its dominance over the global osteoporosis drugs market. Additional factors such as the presence of a well-developed healthcare sector, high per capita healthcare expenditures, and well-spread awareness drives the regional market.

Furthermore, growing markets in the U.S. and Canada backed by the presence of prominent market players impacts the growth of the regional market, positively.  The region is expected to create a significant revenue pocket registering a robust CAGR throughout the forecast period (2017-2022).

The osteoporosis market in the European region accounts for the second-largest market, globally. Factors such as favorable government support and initiatives and the proliferating healthcare sector backed by the resurging economy are radiantly fostering the growth of the market in the region.

The U.K., backed by its sizeable osteoporosis drugs market and Germany with its vast medical technology and pharmaceutical industry, significantly contributes to the growth of the regional market, is expected to drive the market growth in the region. 

The Asia Pacific osteoporosis drugs market is rapidly emerging as a promising market, globally. Factors such as the spreading awareness towards the disorder and women healthcare alongside the availability of many novel drugs influence the growth of the market, positively.

Moreover, the rising prevalence of osteoporosis in women after menopause, gene mutations, changing lifestyle, and the burgeoning pharmaceutical industry support the growth of the regional market. Furthermore, continually rising healthcare expenditures and favorable government policies, especially in the developing countries like China and India substantiate the market growth in the APAC region.

Browse Complete 84 Pages Premium Research Report Enabled with Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479

Global Osteoporosis Drugs Market – Competitive Analysis

Fiercely competitive, the osteoporosis drugs market appears fragmented with many large and small players churning the competition. Through the strategic initiatives such as partnership, expansion, acquisition, collaboration, and product & technology launch these players try to gain an edge over their competitors.

Major Players:

Key players leading the global osteoporosis drugs market include Merck & Co., Eli Lilly and Company, Novartis International AG, F. Hoffmann La Roche Ltd., Amgen Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Novo Nordisk among others.

Industry, Innovation & Related News

April 16, 2019 –--- Two leading global biopharmaceutical companies UCB (Belgium) and Amgen Inc. (the US) announced the receiving of the US FDA approval for the osteoporosis drug – Evenity that they have developed, collaboratively. This drug is approved to treat osteoporosis in postmenopausal women at high risk of bone fracture. Evenity represents the first new treatment approach after nearly two decades, restoring bone without breaking it down. Based on a rare gene mutation in people with bones so dense that they never break, Evenity, can increase bone formation and decrease bone loss.

Send an Enquiry @ https://www.marketresearchfuture.com/enquiry/2479

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Info:
Name: Market Research Future
Email: Send Email
Organization: Market Research Future
Address: Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India
Phone: +1 646 845 9312
Website: https://www.marketresearchfuture.com/reports/osteoporosis-drugs-market-2479

Source URL: https://marketersmedia.com/global-osteoporosis-drugs-market-drivers-and-restraints-in-the-healthcare-insustry-mrfr-unleashes-the-forecast-by-2022/523312

Source: MarketersMedia

Release ID: 523312

More News From digitalpressnetwork.com

Big plastic user Japan fights waste ahead of G-20 summit

Jun 26, 2019

TOKYO — Japan has a plastic problem. In a country where cleanliness and neat packaging have long been considered good service, almost everything, from single bananas to individual pieces of vegetables, pastries, pens and cosmetics is sold plastic-wrapped. But as world leaders descend on Osaka for the two-day G-20 summit that starts Friday, Japan will attempt to become a leader in environmental policy at the same time it plays catch-up with countries that already have well-defined goals in place. In the months leading up to the G-20 summit, Japanese officials have delivered full-throated endorsements of future bans on single-use plastics,...

Dozier's slam leads Royals to 8-6 comeback win over Indians

Jun 26, 2019

CLEVELAND — Hunter Dozier's grand slam capped Kansas City's stunning five-run rally in the ninth inning off Cleveland closer Brad Hand, giving the Royals an 8-6 win over the Indians on Tuesday night. Hand (4-3) was a perfect 22 for 22 in save chances and likely on his way to being an All-Star. But the left-hander did not record an out against the Royals, who entered the ninth down 6-3 before storming back. Nicky Lopez had an RBI infield single before Kansas City loaded the bases and Dozier connected on Hand's first pitch for his first career grand slam and...

Yankees homer in 28th straight game to set MLB record

Jun 26, 2019

NEW YORK — The New York Yankees have homered for the 28th straight game, breaking a major league record. And they wasted no time setting the mark Tuesday night. DJ LeMahieu hit a leadoff shot into the second deck down the left field line against Toronto lefty Clayton Richard, giving the Bronx Bombers sole possession of the record. New York began the night tied at 27 games in a row with the 2002 Texas Rangers, a team that featured Alex Rodriguez and Rafael Palmeiro. The Yankees quickly added another one, too. Aaron Judge followed LeMahieu with an opposite-field drive into...

Copa America happy with video reviews despite some criticism

Jun 26, 2019

RIO DE JANEIRO — The head of refereeing at South America's soccer body Conmebol says he's pleased about the lack of major disputes at the Copa America involving video assisted reviews, despite some controversial decisions during the group stage. Wilson Seneme said Tuesday that Copa America had "no scandals" in the 17 VAR interventions made in the first 18 matches of the tournament. It is the first time Copa America uses the technology, which is present from the opening game to the July 7 final at the Maracana Stadium, although it did not operate at all venues. "We are very...

Port Authority seeking fare, toll hikes across New York area

Jun 26, 2019

NEW YORK — The authority that operates New York's airports and many of its bridges and tunnels is proposing fare and toll hikes across a broad swath of its facilities, some potentially taking effect as early as this fall, to keep pace with inflation and help fund more than $30 billion in capital projects over the next decade. The Port Authority of New York and New Jersey laid out its plans Tuesday to raise tolls at its bridges and tunnels and hike fares on its PATH rail service and on trains to JFK and Newark Liberty International airports. It also...

Weather, 20 December
Houston Weather
+7

High: +11° Low: -2°

Humidity: 83%

Wind: NNE - 7 KPH

Canberra Weather
+27

High: +27° Low: +17°

Humidity: 87%

Wind: W - 20 KPH

Roissy-en-France Weather
+6

High: +6° Low: -5°

Humidity: 87%

Wind: ENE - 7 KPH

Florence Weather
+9

High: +9° Low: +6°

Humidity: 97%

Wind: ENE - 17 KPH

Parga Weather
+7

High: +16° Low: +4°

Humidity: 100%

Wind: SE - 25 KPH